Fig. 4. Ad-vector-mediated anti-tumor efficiency in vivo.
For all experiments 5×105 MMC cells were injected subcutaneously into mice and 1×109 pfu Ad-vector was injected once intratumorally when tumors reached a size of 3–4 mm diameter. A. Survival of SCID and neu-tg mice that were intratumorally injected with mock, PBS, Ad.zero, Ad.lacZ, Ad.IR-E1A/TRAIL or H101. B. Survival of neu-tg mice that were intratumorally injected with mock, PBS, Ad.zero, Ad.αCD3, Ad.αCD137, Ad.IL-15 or Ad.LIGHT. C. Survival of CD4+ T cell-, CD8+ T cell- and NK cell-depleted and non-depleted neu-tg mice that were intratumorally injected with PBS or Ad.zero. D. Survival of Ad pre-immunized and non-immunized neu-tg mice that were intratumorally injected with PBS or Ad.zero. E. ELIspot analysis for Ad-induced IFN-γ secretion. Spleens, sentinel lymph nodes (LN) and tumor-infiltrating lymphocytes (TIL) of neu-tg mice were harvested 10 days after intratumoral injection of Ad.zero or mock. For in vitro sensitization lymphocytes were pulsed with mock (white bars) or Ad.zero (gray bars). Bars indicate mean number of spots ± SD per 1×106 lymphocytes (spleen, LN; left panel) or 2.5×105 TIL (right panel). F. LacZ transcript expression in Ad.lacZ intratumorally injected MMC tumors in SCID and neu-tg mice at different time points after injection quantified via real-time RT PCR. y=1 for SCID tumors (day 2 p.i.). Bars indicate mean and SD. A-D: n=5 animals/group, except for Ad.LIGHT group: n=6); D: n=5 animals/PBS i.t. group, n=7 animals/Ad.zero i.t. group). A-D: x-axis, days post tumor transplantation; y-axis, % survival; E-H: n=3 animals/group. MS, median survival; n.s., not significant; P>0.05, *; P<0.05, **; P<0.01, ***, P<0.001 (logrank test).